| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CD160 |
| Uniprot No | O95971-1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 27-159aa |
| 氨基酸序列 | INITSSASQEGTRLNLICTVWHKKEEAEGFVVFLCKDRSGDCSPETSLKQ LRLKRDPGIDGVGEISSQLMFTISQVTPLHSGTYQCCARSQKSGIRLQGH FFSILFTETGNYTVTGLKQRQHLEFSHNEGTLS |
| 预测分子量 | 16 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CD160重组蛋白的3篇参考文献示例(注：文献信息为模拟概括，实际文献需通过学术数据库验证)：
---
1. **文献名称**: *CD160-HVEM interaction regulates NK cell-mediated cytotoxicity in tumor immunity*
**作者**: Anjuère, F. et al.
**摘要**: 该研究通过重组CD160蛋白探究其与HVEM受体的相互作用机制，发现CD160在NK细胞杀伤肿瘤细胞中起关键调控作用，阻断该通路可增强抗肿瘤免疫应答。
2. **文献名称**: *Structural and functional characterization of recombinant CD160 in T cell activation*
**作者**: Cai, G. et al.
**摘要**: 利用重组CD160蛋白进行X射线晶体学分析，揭示了其分子结构特征，并证明其在T细胞共刺激信号通路中的作用，为自身免疫疾病治疗提供新靶点。
3. **文献名称**: *Recombinant CD160 modulates inflammatory response in viral infection models*
**作者**: Bhatt, S. et al.
**摘要**: 研究重组CD160蛋白在HIV感染模型中的功能，发现其通过调节IFN-γ分泌抑制病毒复制，提示其作为抗病毒免疫治疗剂的潜力。
---
**备注**：以上文献为示例性概括，实际研究中请通过PubMed、Google Scholar等平台检索具体文献(关键词：CD160 recombinant protein, HVEM interaction, NK/T cell function)。
CD160 is a cell surface glycoprotein belonging to the immunoglobulin superfamily, primarily expressed on natural killer (NK) cells, cytotoxic T lymphocytes, and subsets of γδ T cells. It functions as a co-signaling molecule, modulating immune responses through interactions with ligands such as herpesvirus entry mediator (HVEM) and class I major histocompatibility complex (MHC-I). CD160 exists in two isoforms: a glycosylphosphatidylinositol (GPI)-anchored membrane-bound form and a soluble form generated via alternative splicing. Its dual role in immune activation and inhibition depends on cellular context and ligand engagement. For instance, CD160-HVEM binding can enhance NK cell cytotoxicity or promote T cell exhaustion in chronic infections.
Recombinant CD160 protein is engineered to study its structural and functional properties, often produced in mammalian expression systems (e.g., HEK293 or CHO cells) to ensure proper post-translational modifications. This protein typically retains the extracellular domain (amino acids 23-181), which mediates ligand interactions. Researchers utilize it in vitro or in vivo to investigate CD160-mediated signaling pathways, immune checkpoint regulation, and therapeutic targeting. For example, soluble CD160-Fc fusion proteins are employed to block CD160-HVEM interactions in autoimmune or inflammatory disease models.
Interest in CD160 has grown due to its potential as a biomarker or immunotherapeutic target, particularly in cancer and chronic viral infections. Studies suggest CD160 expression correlates with NK cell dysfunction in tumors, while its blockade may restore anti-tumor immunity. However, its pleiotropic effects necessitate careful evaluation in therapeutic contexts. Recombinant CD160 tools remain critical for elucidating its biology and developing targeted interventions.
×
